- What is JaxBio Technologies' primary focus?
- JaxBio Technologies is focused on developing a simple and sensitive blood test for early cancer diagnosis, monitoring disease status, and predicting response to therapy.
- When was JaxBio Technologies founded?
- JaxBio Technologies was founded in January 2022.
- How many employees does JaxBio Technologies currently have?
- JaxBio Technologies has 11-50 employees.
- What is the total amount of funding JaxBio Technologies has raised to date?
- JaxBio Technologies has raised a total of $17,980,000 USD.
- Which organizations have provided grant funding to JaxBio Technologies?
- JaxBio Technologies received a grant from Horizon Europe in January 2023 and another from the European Innovation Council in July 2024.
- What types of cancer is JaxBio Technologies currently focusing on for diagnostic test development?
- JaxBio Technologies is currently focused on developing its first diagnostic tests for lung cancer and hematological malignancies.
- Who are the co-founders of JaxBio Technologies?
- The co-founders of JaxBio Technologies are Shahar Zirkin, Joel Bar-El, Dror Feldheim, and Yuval Ebenstein.
- What is JaxBio Technologies' core technology for cancer detection?
- JaxBio Technologies has developed an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA from blood samples, utilizing a proprietary process to fluorescently label markers and hybridize DNA onto a custom chip to identify unique pixel pattern signatures for cancer classification.
